Tvardi Therapeutics, Inc. (TVRD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 50M 100M 150M FY12: 1.2M FY13: 12M FY14: 3.2M FY15: 3.8M FY16: 86K FY17: 911K FY18: 13.5M FY19: 19.9M FY20: 135.1M FY21: 23M FY22: 41.9M FY23: 21M FY24: 7.1M FY12 FY14 FY16 FY18 FY20 FY22 FY24

Gross Profit Annual

0 8M 16M 24M FY21: 23M FY21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY12: -6.2M FY13: -237K FY14: -18.1M FY15: -25.2M FY16: -58.4M FY17: -59.5M FY18: -77.4M FY19: -111.7M FY20: 5.4M FY21: -89.1M FY22: -87.5M FY23: -121.5M FY24: -28.1M FY25: -26.7M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-150M -100M -50M 0 50M 100M 150M FY12: -6.3M FY13: -4M FY14: -17.7M FY15: -24.7M FY16: -57.3M FY17: -58.1M FY18: -74M FY19: -106.4M FY20: 8.4M FY21: -88.4M FY22: -85.5M FY23: -118.5M FY24: -29.4M FY25: -18.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 FY21: 0 FY21

Operating Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY12: -6M FY13: 2.8M FY14: -17.6M FY15: -21.5M FY16: -47.4M FY17: -54.8M FY18: -22.3M FY19: -109.2M FY20: -5.5M FY21: -60.1M FY22: -78.7M FY23: -92.1M FY24: -18.3M FY25: -23.5M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY13: 2.8M FY14: -17.7M FY15: -21.5M FY16: -48.1M FY17: -54.9M FY18: -22.4M FY19: -109.2M FY20: -5.8M FY21: -60.1M FY22: -78.8M FY23: -94.5M FY24: -19.4M FY14 FY16 FY18 FY20 FY22 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY12: 3.3M FY13: 4.1M FY14: 21M FY15: 24.6M FY16: 27.3M FY17: 31.2M FY18: 35.9M FY19: 42.7M FY20: 47.9M FY21: 50.7M FY22: 4.5M FY23: 4.5M FY24: 2.6M FY25: 7.8M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-27.00 -18.00 -9.00 0.00 9.00 18.00 27.00 Q4 '13: -1.71 Q1 '14: -1.45 Q2 '14: -1.94 Q3 '14: -1.16 Q4 '14: -0.85 Q1 '15: -0.84 Q2 '15: -0.93 Q3 '15: -0.83 Q4 '15: -1.00 Q1 '16: -1.18 Q2 '16: -1.41 Q3 '16: -1.64 Q4 '16: -2.10 Q1 '17: -2.52 Q2 '17: -2.33 Q3 '17: -2.29 Q4 '17: -1.91 Q1 '18: -1.61 Q2 '18: -1.84 Q3 '18: -1.97 Q4 '18: -2.06 Q1 '19: -2.11 Q2 '19: -2.17 Q3 '19: -2.40 Q4 '19: -2.49 Q1 '20: -2.55 Q2 '20: -2.51 Q3 '20: -2.12 Q4 '20: 0.08 Q1 '21: 0.23 Q2 '21: 0.16 Q3 '21: 0.49 Q4 '21: -1.74 Q1 '22: -1.79 Q2 '22: -1.26 Q3 '22: -1.67 Q4 '22: -19.12 Q1 '23: -19.09 Q2 '23: -19.59 Q3 '23: -19.68 Q4 '23: -26.26 Q4 '25: -3.26 Q1 '26: -0.27 Q2 '26: 0.04 Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q1 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.